natgillin/translations-raw huggingface dataset:
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Vsako neporabljeno zdravilo za uporabo v veterinarski medicini ali odpadne snovi,ki nastanejo iz teh zdravil, je treba odstraniti v skladu z lokalnimi predpisi.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Vsako neuporabljeno zdravilo ali odpadne snovi, ki nastanejo iz teh zdravil, je treba odstraniti v skladu z nacionalnimi zahtevami.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with the local requirements.
Vsako neporabljeno zdravilo ali odpadne snovi, ki nastanejo iz teh zdravil, je treba odstraniti v skladu z lokalnimi predpisi.
Any unused veterinary medicinal product, waste materials derived from such veterinary medicinal products or regurgitated intraruminal devices should be disposed of in accordance with local requirements.
Vsako neporabljeno zdravilo za uporabo v veterinarski medicini, odpadne snovi, ki nastanejo iz teh zdravil, ali regurgitirane intraruminalne sisteme je treba odstraniti v skladu z lokalnimi predpisi.
Any unused veterinary medicinal products or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.
Vsako neporabljeno zdravilo za uporabo v veterinarski medicini ali odpadne snovi, ki nastanejo iz teh zdravil, je treba odstraniti v skladu z lokalnimi predpisi.
Any unused veterinary product or waste material derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Vsako neporabljeno zdravilo ali odpadne snovi, ki nastanejo iz teh zdravil, je treba odstraniti v skladu z lokalnimi predpisi.
Any unused veterinary product or waste material derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Vsako neporabljeno zdravilo ali odpadne snovi, ki nastanejo iz teh zdravil, je treba odstraniti v skladu z lokalnimi zahtevami.
Any unused veterinary product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.
Vsako neporabljeno zdravilo za uporabo v veterinarski medicini ali odpadne snovi, ki nastanejo iz teh zdravil, je treba odstraniti v skladu z lokalnimi predpisi.
Any unused veterinary product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Vsako neporabljeno zdravilo ali odpadne snovi, ki nastanejo iz teh zdravil, je treba odstraniti v skladu z lokalnimi predpisi.
any unusual bruising,
kakršna koli neobičajna modrica,
Any used or unused but no longer required medicinal product or waste material should be disposed of in accordance with local requirements.
Vseouporabljeneoali neuporabljeno zdravilo ali odpadni material, ki ga ne uporabljate več, zavrzite v skladu z lokalnimi predpisi.
Any used or unused nasal spray should be returned systematically and discarded according to local requirements or returned to the pharmacy.
Vsa uporabljena ali neuporabljena pršila za nos je treba sistematično vrniti in jih zavreči v skladu z lokalnimi predpisi ali vrniti v lekarno.
Any used or unused patches should be discarded according to local requirements or returned to the pharmacy.
Vse uporabljene in neuporabljene obliže zavrzite v skladu z lokalnimi predpisi oziroma jih vrnite v lekarno.
Any UV-therapy should be discontinued before treatment.
Pred zdravljenjem je treba prekiniti kakršnokoli zdravljenje z UV-žarki.
Any vaccination will need to be given to you at least 6 weeks before starting a LEMTRADA treatment course.
Vsa cepiva boste morali prejeti vsaj šest tednov pred začetkom zdravljenja z zdravilom LEMTRADA.
Any Ventavis solution remaining in the nebuliser after inhalation must be thrown away (see section 5).
Celotno raztopino zdravila Ventavis, ki po inhalaciji ostane v nebulatorju, je treba zavreči (glejte poglavje 5).
Any Ventavis solution remaining in the nebuliser after inhalation must be thrown away.
Celotno raztopino zdravila Ventavis, ki po inhalaciji ostane v nebulatorju, morate zavreči.
Any Ventavis solution remaining in the nebuliser must be thrown away.
Celotno raztopino zdravila Ventavis, ki po inhalaciji ostane v nebulatorju, morate zavreči.
Any vial showing signs of damage or tampering must not be used.
Viale, na kateri so vidne poškodbe ali znaki predhodnega odpiranja pečata, ne smete uporabiti.
Any waste material should be disposed of in accordance with local requirements.
Neuporabljeno zdravilo ali odpadni material je treba odvreči v skladu z lokalnimi zahtevami.
Any woman who has missed a period should be assumed to be pregnant until proven otherwise.
Vsako žensko, ki ji je izostala menstruacija, moramo obravnavati, kot da je noseča, dokler se ne dokaže nasprotno.
Any woman who has missed a period should be assumed to be pregnant until proven otherwise. .
Ženske z izostalo menstruacijo morate obravnavati kot noseče, dokler ne dokažete drugače.
Anyone experiencing such symptoms should immediately be transported to a hospital emergency room for evaluation and treatment. temporary non-infectious meningitis (reversible aseptic meningitis),
Vsakega bolnika, ki ima te simptome, je treba takoj prepeljati v urgentno enoto bolnišnice za oceno simptomov in zdravljenje. začasnem neinfekcioznem meningitisu (reverzibilni aseptični meningitis),
Anyone handling Siklos should wash their hands before and after contact with the tablets.
Vsi, ki rokujejo z zdravilom Siklos, si morajo pred stikom s tabletami in po njem umiti svoje roke.
Anyone in your household who administers Palladia to your dog should always wash their hands after handling the tablets.
Kdorkoli daje zdravilo Palladia vašemu psu, si naj po rokovanju s tabletami vedno umije roke.
Anyone taking Ziagen could develop a hypersensitivity reaction to abacavir, which could be life threatening if they continue to take Ziagen.
Preobčutljivostna reakcija na abakavir se lahko pojavi vsakomur, ki jemlje zdravilo Ziagen, in je lahko življenjsko nevarna, če ne prenehajo jemati zdravilo Ziagen.
anyone who has had pancreatitis (inflammation of the pancreas)
pri osebah, ki so imele pankreatitis (vnetje trebušne slinavke)
Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy
Stenoza aortne in mitralne zaklopke ter obstruktivna hipertrofična kardiomiopatija
Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy
Stenoza aortne in mitralne zaklopke, obstruktivna hipertrofična kardiomiopatija
Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy
Stenoza aortne in mitralne zaklopke, obstruktivna hipertrofična kardiomiopatija:
Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy:
Stenoza aortne in mitralne zaklopke, obstruktivna hipertrofična kardiomiopatija
aortic aneurysm,
aortna anevrizma,
Aortic aneurysm, arterial occlusive disease, capillary disorder, embolism, haematoma, haemorrhage, intermittent claudication, lymphostasis, thrombosis, vascular stenosis, venous thrombosis, venous thrombosis limb
aortna anevrizma, okluzivna bolezen arterij, bolezen kapilar, embolizem, hematom, krvavitev, intermitentna klavdikacija, limfostaza, tromboza, stenoza žil, venska tromboza, venska tromboza v udih
aOther includes shoulder, back, leg.
a Drugo vključuje ramo, hrbet, nogo.
aOther includes shoulder, back, leg.
aDrugo vključuje ramo, hrbet, nogo.
aOther standard therapies were used as appropriate.
a Ostala standardna zdravljenja so bila ustrezno uporabljena.
ap value is adjusted for region and duration of RA for all endpoints and additionally baseline value for all continuous endpoints. b Non-responder Imputation used for missing data.
a p vrednost je prilagojena glede na regijo in trajanje revmatoidnega artritisa za vse končne cilje ter dodatno za začetno vrednost pri vseh nadaljnjih končnih ciljih. b Za manjkajoče podatke so uporabili imputacijo za neodzivne bolnike.
AP-CML (N=85) (%)
AP-KML (N = 85) (%)
ap-value calculated using Cochran-Mantel-Haenszel statistic blocked by baseline platelet count bStatistically significantly more patients achieved ≥ 6 x 106 cells/kg in ≤ 2 apheresis days with Mozobil and G-CSF (n=106; 71.6%) than with placebo and G-CSF (n=53; 34.4%), p<0.001; statistically significantly more patients achieved
a p-vrednost je izračunana na osnovi statističnega postopka Cochran-Mantel-Haenszel in omejena z izhodiščno vrednostjo trombocitov. b Statistično značilno več bolnikov je doseglo ≥ 6 x 106 celic/kg v ≤ 2 dneh afereze z zdravilom Mozobil in G-CSF (n = 106; 71,6 %) kot s placebom in G-CSF (n = 53; 34,4 %), p < 0,001; statistično značilno več bolnikov je doseglo ≥ 6 x
ap<0.0001 for assessment of non-inferiority to PRN
ap<0,0001 za oceno neinferiornosti v primerjavi s shemo pro re nata
ap<0.0001 for comparisons of ranibizumab arms vs. laser arm. n in D2301-E1 (RESTORE Extension) is the number of patients with a value at both D2301 (RESTORE) baseline (Month 0) and at the Month 36 visit.
ap<0,0001 za primerjavo skupine z ranibizumabom s skupino z laserjem n v študiji D2301-E1 (v podaljšanju študije RESTORE) je število bolnikov, pri katerih je bila znana tako izhodiščna vrednost v študiji D2301 (RESTORE) (mesec 0) kot vrednost, izmerjena na obisku po 36 mesecih zdravljenja.
ap<0.0001for both studies
ap<0,0001 za obe študiji
Apache II score ≤ 20
Seštevek Apache II ≤ 20
Apache II score  20
Seštevek Apache II  20
Apart from a reduced T-cell Dependent Antibody Response in cynomolgus monkeys immunized with KLH after 3 months of treatment with evolocumab, no adverse effects were observed in hamsters (up to 3 months) and cynomolgus monkeys (up to 6 months) at exposures much higher than patients receiving evolocumab at 420 mg once monthly.
Razen zmanjšanja od celic T odvisnega odziva protiteles pri opicah cynomolgus, cepljenih s KLH 3 mesece po zdravljenju z evolokumabom, pri hrčkih (do 3 mesece) in opicah cynomolgus (do 6 mesecev) niso opazili neželenih učinkov ob izpostavljenostih, veliko večjih kot pri bolnikih, zdravljenih s 420 mg evolokumaba enkrat na mesec.
Apart from adrenal blocking effect, ketoconazole may also have direct effects on corticotropic tumour cells in patients with Cushing’s disease.
Poleg zaviralnega učinka na nadledvične žleze ima lahko ketokonazol neposredne učinke tudi na kortikotropne tumorske celice pri bolnikih s Cushingovo boleznijo.
Apart from dose-dependent increases in incidences of somnolence and fatigue brivaracetam 50 mg/day and 100 mg/day had a similar safety profile including CNS- related AEs and with long-term use.
Razen povečanj incidence somnolence in utrujenosti, odvisnih od odmerka, je brivaracetam v odmerku 50 mg/dan in 100 mg/dan imel podoben varnostni profil, vključno z neželenimi učinki, povezanimi s centralnim živčnim sistemom, in dolgotrajno uporabo.
Apart from erythema and cosmetic hair coat changes at the site of application, no adverse reactions were observed in healthy puppies aged 7 weeks, topically treated 7 times at 2 week intervals and with up to 5 times the highest recommended dose.
Razen rdečice in kozmetičnega učinka na dlako na mestu nanosa, ni bilo opaženih neželenih učinkov pri zdravih mladičih starih 7 tednov, ki so jim dali sredstvo 7 krat v dvotedenskih razmikih in v do 5 kratnem priporočenem odmrku.
Apart from local skin redness and cosmetic hair coat changes where the medicine was applied, no adverse reactions were observed in healthy puppies aged 7 weeks, given the medicine on the skin 7 times at 2-week intervals and with up to 5 times the highest recommended dose.
Razen rdečice in kozmetičnega učinka na dlako na mestu nanosa, ni bilo opaženih neželenih učinkov pri zdravih mladičih starih 7 tednov, ki so jim dali sredstvo 7 krat v dvotedenskih razmikih in v do 5 kratnem priporočenem odmerku.
Apart from one lactam metabolite, the identity of other metabolites is not known in cats or dogs.
Identiteta presnovkov pri mačkah in psih, razen enega laktamskega, ni znana.
Apart from one lactam metabolite, the identity of other metabolites is not known in cats.
Identiteta presnovkov pri mačkah, razen enega laktamskega, ni znana.
Apart from one lactam metabolite, the identity of other metabolites is not known in dogs.
Identiteta presnovkov pri psih, razen enega laktamskega, ni znana.
Apart from symptoms associated with hypersensitivity reactions IRRs might show as fatigue, dizziness, pyrexia, blood pressure increase or pruritus.
Poleg simptomov, povezanih s preobčutljivostnimi reakcijami, se lahko IRR pokažejo kot utrujenost, omotica, zvišana telesna temperatura ali pruritus.
Apart from symptoms of hypersensitivity reactions infusion-related reactions might show as dizziness, high blood pressure, tiredness, fever, or itching.
Poleg simptomov preobčutljivostnih reakcij se lahko reakcije, povezane z infundiranjem, pokažejo kot omotica, visok krvni tlak, utrujenost, zvišana telesna temperatura ali srbenje.
Apart from transient reactions at the injection site following subcutaneous administration, Cerenia solution for injection was well tolerated in dogs and young cats injected daily with up to 5 mg/kg (5 times the recommended dose) for 15 consecutive days (3-times the recommended duration of administration).
Z izjemo prehodnih reakcij na mestu injiciranja po subkutanem dajanju, so injiciranje odmerka do 5 mg/kg (5x večji odmerek od priporočenega) 15 zaporednih dni (3x daljše obdobje od priporočenega) psi in mlade mačke dobro prenašali.
apart)
razmaku 12 ur)
Apathy Depersonalisation Drug dependence Euphoric mood Hostility
evforično razpoloženje sovražnost
Apathy* Nervousness*
Apatija* Živčnost
Apathy, depression, nervousness, agitation, irritability, attention deficit/ hyperactivity disorder, confusional state, mood swings, crying, psychomotor retardation, psychotic disorder
apatija, depresija, živčnost, agitacija, razdražljivost, motnje pozornosti/hiper aktivnost, stanje zmedenosti, spremembe razpoloženja, jok, psihomotorična retardacija, psihotične motnje
aPercents determined by Kaplan Meier method
a Odstotki so izračunani po metodi Kaplan Meier.
APEX study: During the 8-week prophylaxis period, a greater proportion of subjects in the febuxostat 120 mg (36%) treatment group required treatment for gout flare compared to febuxostat 80 mg (28%), allopurinol 300 mg (23%) and placebo (20%).
Študija APEX: V času 8 tedenskega preventivnega zdravljenja je večji delež oseb potreboval zdravljenje zagona putike v skupini s 120 mg febuksostata (36 %), kot v skupini s febuksostatom 80 mg (28 %), alopurinolom 300 mg (23 %) in placebo (20 %) skupinah.
Aphakia, chorioretinopathy, conjunctival haemorrhage, conjunctival hyperaemia, eye haemorrhage, eye pruritus, eyelid oedema, keratoconjunctivitis sicca, macular degeneration, ocular hyperaemia, pupils unequal, retinal detachment, retinal vascular disorder, retinopathy, visual acuity reduced, visual disturbance
afakija, horioretinopatija, konjunktivalna krvavitev, konjunktivalna hiperemija, očesna krvavitev, očesni pruritus, edem očesne veke, suhi keratokonjunktivitis, makularna degeneracija, očesna hiperemija, neenaki zenici, odstop mrežnice, bolezen mrežničnih žil, retinopatija, zmanjšana ostrina vida, motnja vida
Aphakic eyes with ruptured posterior lens capsule.
Afakično oko z raztrgano posteriorno kapsulo leče.
Aphasia, Memory impairment, Ataxia, Syncope, Balance disorder, Sensory disorder, Neuropathy peripheral
afazija, motnje spomina, ataksija, sinkopa, motnje ravnotežja, motnje zaznavanja, periferna nevropatija
Apheresis catheter care sheets
Dokumentacijo za vzdrževanje katetrov za aferezo
Aphonia
afonija
Aphthous stomatitis
aftozni stomatitis
Apidra 100 Units/ml solution for injection in a cartridge
Apidra 100 enot/ml raztopina za injiciranje v vložku
Apidra 100 Units/ml solution for injection in a cartridge for OptiClik
Apidra 100 enot/ml raztopina za injiciranje v vložku za Opti Clik
Apidra 100 Units/ml solution for injection in a cartridge for OptiClik is a clear, colourless, aqueous solution with no particles visible.
Apidra 100 enot/ml, raztopina za injiciranje v vložku za OptiClik je bistra, brezbarvna, vodna raztopina brez vidnih delcev.
Apidra 100 Units/ml solution for injection in a cartridge is a clear, colourless, aqueous solution with no particles visible.
Apidra 100 enot/ml, raztopina za injiciranje v vložku je bistra, brezbarvna, vodna raztopina brez vidnih delcev.
Apidra 100 Units/ml solution for injection in a pre-filled pen
Apidra 100 enot/ml raztopina za injiciranje v napolnjenem injekcijskem peresniku
Apidra 100 Units/ml, solution for injection in a cartridge for OptiClik.
Apidra 100 enot/ml raztopina za injiciranje v vložku za OptiClik
Apidra 100 Units/ml, solution for injection in a cartridge.
Apidra 100 enot/ml raztopina za injiciranje v vložku.
Apidra 100 Units/ml, solution for injection in a vial Insulin glulisine
Apidra 100 enot/ml raztopina za injiciranje v viali insulin glulisin
Apidra can be administered intravenously, which should be carried out by health care professionals.
Zdravilo Apidra je mogoče dati tudi intravensko, vendar ga sme tako uporabiti samo zdravstveno osebje.
Apidra in cartridge for OptiClik has been developed for use in OptiClik only.
Apidra v vložkih za OptiClik je pripravljena samo za uporabo v injekcijskem peresniku OptiClik.
Apidra insulin glulisine
Apidra insulin glulisin
Apidra is an antidiabetic agent, used to reduce high blood sugar in patients with diabetes mellitus; it may be given to adults, adolescents and children, 6 years of age and older.
Apidra se uporablja za znižanje visokega krvnega sladkorja bolnikih s sladkorno boleznijo; uporabljajo jo lahko odrasli, mladostniki in otroci stari 6 let ali več.
Apidra may be used for Continuous Subcutaneous Insulin Infusion (CSII) in pump systems suitable for insulin infusion with the appropriate catheters and reservoirs.
Zdravilo Apidra se lahko uporablja za kontinuirano subkutano infundiranje insulina (CSII- Continuous Subcutaneous Insulin Infusion) v sistemih s črpalko, primernih za infundiranje insulina z ustreznimi katetri in rezervoarji.
Apidra must never be mixed with diluents or any other insulin when used in a pump.
Če je zdravilo Apidra uporabljeno v črpalki, ga ne smete mešati z redčili in tudi ne s kakšnim drugim insulinom.
Apidra must not be mixed with glucose or Ringer’s solution or with any other insulin.
Zdravila Apidra se ne sme mešati z raztopino glukoze, Ringerjevo raztopino ali s katerimkoli drugim insulinom.
Apidra should be given by subcutaneous injection shortly (0-15 min) before or soon after meals or by continuous subcutaneous pump infusion.
Apidra se uporablja v subkutani injekciji tik (0–15 minut) pred obroki ali kmalu po njih ali stalni subkutani infuziji s črpalko.
Apidra should be given by subcutaneous injection shortly (0-15 min) before or soon after meals or by continuous subcutaneous pump infusion.
Zdravilo Apidra se uporablja v subkutani injekciji tik (0–15 minut) pred obroki ali kmalu po njih ali stalni subkutani infuziji s črpalko.
Apidra should be taken shortly (0-15 minutes) before or soon after meals.
Zdravilo Apidra je treba uporabiti kratek čas (0–15 minut) pred obroki ali kmalu po njih.
Apidra SoloStar 100 Units/ml solution for injection in a pre-filled pen
Apidra SoloStar 100 enot/ml raztopina za injiciranje v napolnjenem injekcijskem peresniku
Apidra was found to be incompatible with Glucose 5% solution and Ringer’s solution and, therefore, must not be used with these solution fluids.
Ugotovljeno je, da je zdravilo Apidra inkompatibilno s 5 % raztopino glukoze in z Ringerjevo raztopino, zato se ga ne sme uporabljati s tema raztopinama.
Apidra with alcohol
Zdravilo Apidra skupaj s hrano pijačo in alkoholom
Apix.
Izidi krvavitev
Apixaban
apiksaban
Apixaban AUC: ↑ 2-fold
Apiksaban AUC: ↑ 2-krat
Apixaban Dabigatran etexilate Rivaroxaban
apiksaban dabigatraneteksilat rivaroksiban
Apixaban did not induce CYP1A2, CYP2B6, CYP3A4/5 at a concentration up to 20 M.
Apiksaban pri koncentracijah do 20 M ni induciral CYP1A2, CYP2B6, CYP3A4/5.
Apixaban efficacy in initial treatment of VTE was consistent between patients who were treated for a PE [Relative Risk 0.9; 95% CI (0.5, 1.6)] or DVT [Relative Risk 0.8; 95% CI (0.5, 1.3)].
Učinkovitost apiksabana pri začetnem zdravljenju VTE je bila konsistentna med bolniki, zdravljenimi zaradi PE (relativno tveganje 0,9; 95 % IZ (0,5, 1,6)) ali zaradi GVT (relativno tveganje 0,8; 95 % IZ (0,5, 1,3)).
Apixaban inhibits free and clot-bound factor Xa, and prothrombinase activity.
Apiksaban zavira prosti in na strdek vezani faktor Xa ter aktivnost protrombinaze.
Apixaban is a substrate of transport proteins, P-gp and breast cancer resistance protein (BCRP).
Apiksaban je substrat za prenašalna proteina P-gp in rezistentni protein, izoliran pri raku dojke (BCRP; “breast cancer resistance protein”).
Apixaban is rapidly absorbed with maximum concentrations (Cmax) appearing 3 to 4 hours after tablet intake.
Največje koncentracije (Cmax) so dosežene od 3 do 4 ure po zaužitju tablete.
Apixaban N = 2,798 n(%/year)
n = 2.676 n (%)
Apixaban N = 2,807 n (%/year)
n = 2.609 n (%)
Apixaban N=9,120 n (%/yr)
apiksaban n = 9.120
aplasia pure red cell
čista aplastična anemija
Aplasia pure red cell
čista aplazija eritrocitov
Aplasia, Gastrointestinal malformation, Ichthyosis
aplazija, gastrointestinalne malformacije, ihtioza
aplastic anaemia,
anemija,
aplastic anaemia, pancytopenia, agranulocytosis, severe thrombocytopenia, granulocytopenia, anaemia
huda trombocitopenija, granulocitopenija, anemija
aplastic anaemia, pure red cell aplasia (a condition where the body stopped or reduced the
aplastično anemijo, aplazijo rdečih krvnih celic (stanje, pri katerem telo preneha izdelovati rdeče krvne celice oziroma se njihovo nastajanje zmanjša).
aplastic anaemia, pure red cell aplasia (a condition where the body stopped or reduced the production of red blood cells); this causes severe anaemia, symptoms of which would include unusual tiredness and a lack of energy,
aplastično anemijo, aplazijo rdečih krvnih celic (stanje, pri katerem telo preneha izdelovati rdeče krvne celice oziroma se njihovo nastajanje zmanjša): ta motnja povzroči hudo anemijo, med njene simptome pa sodijo neobičajna utrujenost in pomanjkanje energije,
Aplastic anaemiah
aplastična anemijah
Apnoea in premature babies is due to the baby’s breathing centres in the brain not being fully developed.
Do apneje pri nedonošenčkih pride zato, ker dihalni centri v njihovih možganih še niso povsem razviti.
Apnoea in very premature infants (born ≤ 28 weeks of gestation) (see section 4.4) Reporting of suspected adverse reactions
Apneja pri veliko prezgodaj rojenih nedonošenčkih (rojenih v 28. tednu nosečnosti ali prej) (glejte poglavje 4.4)
Apnoea in very premature infants (born ≤28 weeks of gestation) (see section 4.4)
Apneja pri veliko prezgodaj rojenih nedonošenčkih (rojenih v 28. tednu nosečnosti ali prej) (glejte poglavje 4.4).
Apnoea in very premature infants (≤ 28 weeks of gestation) (see section 4.4)
28. tednu nosečnosti) (glejte poglavje 4.4)
Apnoea in very premature infants (≤ 28 weeks of gestation) (see section 4.4)
apneja pri veliko prezgodaj rojenih nedonošenčkih (rojenih pred ali v
Apnoea in very premature infants (≤ 28 weeks of gestation) (see section 4.4)
Apneja pri veliko prezgodaj rojenih nedonošenčkih (rojenih pred ali v 28. tednu nosečnosti) (glejte poglavje 4.4).
Apnoea in very premature infants (≤28 weeks of gestation) (see section 4.4)
apneja pri zelo nedonošenih otrocih (≤ 28 tednov nosečnosti) (glejte poglavje 4.4)
Apnoea in very premature infants (≤28 weeks of gestation). (See section 4.4).
Apneja pri zelo prezgodaj rojenih dojenčkih (v 28. tednu gestacije ali prej) (glejte poglavje 4.4).
Apnoea in very premature infants ( 28 weeks of gestation) (see section 4.4).
Apneja pri veliko prezgodaj rojenih nedonošenčkih (rojenih pred 28. tednom ali v 28. tednu nosečnosti) (glejte poglavje 4.4).